Princeton Global Asset Management LLC Buys Shares of 294 Boston Scientific Corporation $BSX

Princeton Global Asset Management LLC bought a new stake in Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 294 shares of the medical equipment provider’s stock, valued at approximately $32,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. 1248 Management LLC acquired a new stake in Boston Scientific in the first quarter valued at $26,000. Y.D. More Investments Ltd acquired a new stake in Boston Scientific in the first quarter valued at $27,000. Sound Income Strategies LLC lifted its holdings in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares during the period. Oliver Lagore Vanvalin Investment Group acquired a new stake in Boston Scientific in the second quarter valued at $37,000. Finally, Activest Wealth Management lifted its holdings in Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 373 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Down 0.6%

Boston Scientific stock opened at $99.88 on Wednesday. The stock has a market cap of $148.00 billion, a PE ratio of 59.45, a P/E/G ratio of 2.42 and a beta of 0.61. The stock has a 50-day moving average price of $101.19 and a 200 day moving average price of $101.83. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm’s quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.62 EPS. Equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Truist Financial raised their price target on Boston Scientific from $125.00 to $129.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Barclays raised their price target on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Wells Fargo & Company raised their price target on Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a research report on Thursday, July 24th. Robert W. Baird raised their price target on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Finally, Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and raised their price target for the company from $118.00 to $125.00 in a research report on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $121.61.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.